United Neuroscience To Move Forward Alzheimer's Vaccine After Promising Phase IIa
Executive Summary
It's early days yet and Alzheimer's is a field littered with failures, but the latest results for the vaccine UB-311 support advancing development.
You may also be interested in...
J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies
Companies working on cell and gene therapies and novel approaches to neurological diseases participated in a roundtable discussion during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.
J.P. Morgan Roundtable: The Regulatory Role In Accelerating Complex Therapies
Part 3: Scrip spoke with companies working on cell and gene therapies and novel approaches to neurological diseases during the J.P. Morgan Healthcare Conference about how regulators are supporting novel modalities, which in turn improves investor and partner sentiment.
J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies
Part 1: Scrip spoke with companies working on cell and gene therapies and novel neuroscience platforms – areas difficult to finance in the past, but seeing increasing investor interest – about funding challenges and opportunities in 2019.